PMC9149407_01
Pathological diagnosis of bone marrow puncture specimens. Magnification is x400. H&E staining (a), E-cadherin-negative (b), AE1/3-positive (c), GATA3-positive (d), estrogen receptor-positive (e), progesterone receptor-negative (f), and HER2-negative (g).
cro-0015-0436-g01.jpg
PMC9149407_01_cro-0015-0436-g01.jpg
F1
Thus, bone marrow metastasis of primary invasive lobular carcinoma of the breast was considered (Fig. 1).
PMC9149407_02
Pathological diagnosis of needle biopsy specimen of breast tumor. Magnification is x400. H&E staining (a), E-cadherin-negative (b), estrogen receptor-positive (c), progesterone receptor-negative (d), and HER2-negative (e).
cro-0015-0436-g02.jpg
PMC9149407_02_cro-0015-0436-g02.jpg
F2
PR: J-Score 1, HER2[-]) (Fig. 2). PET-CT showed left breast cancer, lymph node metastasis, bone metastasis, and peritoneal dissemination (Fig. 3a).
PET-CT image. a PET-CT before the start of treatment. b PET-CT image 6 months after the treatment started, showing improvement in bone metastasis.
cro-0015-0436-g03.jpg
PMC9149407_02_cro-0015-0436-g03.jpg
F3
PR: J-Score 1, HER2[-]) (Fig. 2). PET-CT showed left breast cancer, lymph node metastasis, bone metastasis, and peritoneal dissemination (Fig. 3a). Six months after the start of treatment, PET-CT showed reduction of the primary tumor and improvement of bone metastasis (Fig. 3b).
Changes in Hb and Plts during treatment. pRBC, packed red blood cells.
cro-0015-0436-g04.jpg
PMC9149407_02_cro-0015-0436-g04.jpg
F4
The clinical courses of tumor markers and blood findings are shown in Figures 4 and 5.
Changes in carcinoembryonic antigen levels during treatment.
cro-0015-0436-g05.jpg
PMC9149407_02_cro-0015-0436-g05.jpg
F5
The clinical courses of tumor markers and blood findings are shown in Figures 4 and 5.